Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Appendix A Supplementary data br References br Bourhis

    2020-08-18


    Appendix A. Supplementary data
    References
    [3] Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a
    74 Benefits of deep learning for delineation of SB 431542 at risk in head and neck cancer
    [4] Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 2014;111:360–5. https://doi.org/ 10.1016/j.radonc.2014.06.001.
    [5] Bayman E, Prestwich RJD, Speight R, Aspin L, Garratt L, Wilson S, et al. Patterns of failure after intensity-modulated radiotherapy in head and neck squamous cell carcinoma using compartmental clinical target volume delineation. Clin Oncol 2014;26:636–42. https://doi.org/10.1016/j.clon.2014.05.001. [6] Nuyts S, Dirix P, Clement PMJ, Vander Poorten V, Delaere P, Schoenaers J, et al. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1088–95. https://doi.org/10.1016/j. ijrobp.2008.05.042.
    [13] Lin Peng Y, Chen L, Zhu Shen G, Ning Li Y, Jin Yao J, Wei Xiao W, et al. Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma. Oral Oncol 2018;82:1–7. https://doi. org/10.1016/j.oraloncology.2018.04.025.
    [15] Piotrowski T, Gintowt K, Jodda A, Ryczkowski A, Bandyk W, Ba KB, et al. Impact of the intra- and inter-observer variability in the delineation of parotid glands on the dose calculation during head and neck helical tomotherapy. Technol Cancer Res Treat 2014. https://doi.org/10.7785/tcrtexpress.2013.600278. [16] Yi SK, Hall WH, Mathai M, Dublin AB, Gupta V, Purdy JA, et al. Validating the RTOG-endorsed brachial plexus contouring atlas: An evaluation of reproducibility among patients treated by intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012;82:1060–4. https://doi.org/10.1016/j.ijrobp.2010.10.035.
    [19] Tao C, Yi J, Chen N, Ren W, Cheng J, Tung S, et al. Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma : a multi-institution clinical study. Radiother Oncol 2015;115:407–11. https:// doi.org/10.1016/j.radonc.2015.05.012.
    [32] Vandewinckele L, Robben D, Crijns W, Maes F. Segmentation of head and neck organs-at-risk in longitudinal ct scans combining deformable registrations and convolutional neural networks. Springer International Publishing; 2018. doi:10.1007/978-3-319-67558-9.
    Asian Journal of Surgery xxx (xxxx) xxx
    Available online at www.sciencedirect.com
    ScienceDirect
    ORIGINAL ARTICLE
    Benefits of repeated resections for liver and lung metastases from colorectal cancer
    Kwan Mo Yang a, In Ja Park b,*, Jong Lyul Lee b, Chan Wook Kim b, Yong Sik Yoon b, Seok-Byung Lim b, Chang Sik Yu b, Jin Cheon Kim b
    a Department of General Surgery, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Republic of Korea
    b Department of Colon and Rectal Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
    KEYWORDS
    Colorectal cancer; Metastasectomy; Oncologic outcome; Repeated resection 
    Summary Objective: We aimed to evaluate oncological outcomes after repeat metastasec-tomies in patients having undergone previous resections for colorectal cancer metastases. Methods: We examined 248 patients who underwent metastasectomies for lung and/or liver metastases at our center during a 7-year period, from January 2005 to December 2011. Recurrence-free survival 1 (RFS1) after the metastasectomy for the initial recurrence, recurrence-free survival 2 (RFS2) after the second, and recurrence-free survival 3 (RFS3) after the third repeated resections for recurrence were assessed. The overall survival (OS) rate after the first metastasectomy for the first recurrence (OS) was also assessed.
    Conclusion: A second metastasectomy should be considered the optimal treatment for a sec-ond recurrence. However, careful considerations should be made before performing a third metastasectomy.
    * Corresponding author. Division of Colon and Rectal Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical
    1015-9584/ª 2019 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    Please cite mouth article as: Yang KM et al., Benefits of repeated resections for liver and lung metastases from colorectal cancer, Asian Journal of Surgery, https://doi.org/10.1016/j.asjsur.2019.03.002